Related Experiment Videos
Amikacin treatment of Serratia septicemia in critically ill patients
Abstract:
Serratia marcescens septicemia represents a serious problem in high risk critical care patients. Treatment is difficult because Serratia is usually resistant to most antibiotics. Amikacin is at present the most effective antibiotic in vitro against gentamycin-resistant Serratia, although significant loss of activity may occur in vivo in the group of compromised patients, whose ultimate prognosis may depend eventually upon other associated conditions. In this Medical ICU, 15 patients with Serratia septicemia who were treated with in vitro effective antibiotics (14 were given amikacin) had a mortality of 60%, while 5 patients who received ineffective in vitro antibiotics had a mortality of 100%. In this ICU, 80% of the Serratia isolates were resistant to gentamycin, while only 2.8% were resistant to amikacin. Because amikacin-resistant strains of Serratia have already emerged, appropriate use of this antibiotic is essential in order not to promote the selection of amikacin-resistant strains.
Insights
Serratia marcescens septicemia is a critical care challenge due to antibiotic resistance. Amikacin shows efficacy, but judicious use is vital to prevent resistance development in Serratia strains.
Area of Science:
- Critical Care Medicine
- Infectious Diseases
- Microbiology
Background:
- Serratia marcescens septicemia poses a significant threat to high-risk patients in critical care settings.
- Treatment is often complicated by the bacterium's intrinsic resistance to many antibiotics.
Purpose of the Study:
- To evaluate the in vitro antibiotic susceptibility of Serratia isolates.
- To assess the clinical outcomes of patients with Serratia septicemia treated with effective versus ineffective antibiotics.
Main Methods:
- Retrospective analysis of 20 patients with Serratia septicemia in a Medical Intensive Care Unit (ICU).
- Review of antibiotic susceptibility testing results for Serratia isolates.
- Comparison of mortality rates between patients receiving antibiotics with in vitro efficacy versus those receiving ineffective antibiotics.
Main Results:
- High rates of gentamycin resistance (80%) were observed in Serratia isolates, compared to low amikacin resistance (2.8%).
- Patients treated with effective antibiotics (predominantly amikacin) had a 60% mortality rate.
- Patients treated with ineffective antibiotics experienced 100% mortality.
Conclusions:
- Amikacin demonstrated superior in vitro activity against gentamycin-resistant Serratia isolates.
- Appropriate antibiotic selection significantly impacts patient outcomes in Serratia septicemia.
- Emergence of amikacin-resistant strains necessitates careful antibiotic stewardship to preserve therapeutic options.